Takeshi Matsubara

Takeshi Matsubara

Auto-generated profile, based on publicly available information

Takeshi Matsubara

Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2015 in Diabetes
Verified
Journal Article
Closed access
PDF file
TMTakeshi Matsubara
Takeshi Matsubara
MAMakoto Araki
Makoto Araki
HAHideharu Abe
Hideharu Abe
OUOtoya Ueda
Otoya Ueda
KJKou-Ichi Jishage
Kou-Ichi Jishage
TDToshio Doi
Toshio Doi
Diabetic nephropathy is the leading cause of end-stage renal disease. It is pathologically characterized by the accumulation of extracellular matrix in the mesangium, of which the main component is α1/α2 type IV collagen (Col4a1/a2). Recently, we identified Smad1 as a direct regulator of Col4a1/a2 under diabetic conditions in vitro. Here, we demonstrate that Smad1 plays a key role in diabetic nephropathy through bone morphogenetic protein 4 (BMP4) in vivo. Smad1-overexpressing mice (Smad1-Tg) were established, and diabetes was induced by streptozotocin. Nondiabetic Smad1-Tg did not exhibit histological changes in the kidney; however, the induction of diabetes resulted in an ∼1.5-fold greater mesangial expansion, consistent with an increase in glomerular phosphorylated Smad1. To address regulatory factors of Smad1, we determined that BMP4 and its receptor are increased in diabetic glomeruli and that diabetic Smad1-Tg and wild-type mice treated with a BMP4-neutralizing antibody exhibit decreased Smad1 phosphorylation and ∼40% less mesangial expansion than those treated with control IgG. Furthermore, heterozygous Smad1 knockout mice exhibit attenuated mesangial expansion in the diabetic condition. The data indicate that BMP4/Smad1 signaling is a critical cascade for the progression of mesangial expansion and that blocking this signal could be a novel therapeutic strategy for diabetic nephropathy.

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HAHideharu Abe
Hideharu Abe
TTTatsuya Tominaga
Tatsuya Tominaga
TMTakeshi Matsubara
Takeshi Matsubara
NANaoko Abe
Naoko Abe
SKSeiji Kishi
Seiji Kishi
TDToshio Doi
Toshio Doi
Activation of mesangial cells (MCs), which is characterized by induction of smooth muscle α-actin (SMA) expression, contributes to a key event in various renal diseases; however, the mechanisms controlling MC differentiation are still largely undefined. Activated Smad1 induced SMA in a dose-dependent manner in MCs. As a direct regulating molecule for SMA, we identified and characterized scleraxis (Scx) as a new phenotype modulator in advanced glycation end product (AGE)-exposed MCs. Scx physically associated with E12 and bound the E-box in the promoter of SMA and negatively regulated the AGE-induced SMA expression. Scx induced expression and secretion of bone morphogenetic protein 4 (BMP4), thereby controlling the Smad1 activation in AGE-treated MCs. In diabetic mice, Scx was concomitantly expressed with SMA in the glomeruli. Inhibitor of differentiation 1 (Id1) was further induced by extended treatment with AGE, thereby dislodging Scx from the SMA promoter. These data suggest that Scx and Id1 are involved in the BMP4-Smad1-SMA signal transduction pathway besides the TGFβ1-Smad1-SMA signaling pathway and modulate phenotypic changes in MCs in diabetic nephropathy.

16 July 2023 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YAYusuke Ando
Yusuke Ando
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
HSHideki Shimodaira
Hideki Shimodaira
NTNao Takano
Nao Takano
ESEmiko Sakaida
Emiko Sakaida
MYMotoko Yanagita
Motoko Yanagita

4 July 2023 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
RARyota Akagi
Ryota Akagi
AIAkira Ishii
Akira Ishii
KKKeiichi Kaneko
Keiichi Kaneko
NKNaoya Kondo
Naoya Kondo
HYHideki Yokoi
Hideki Yokoi
MYMotoko Yanagita
Motoko Yanagita
Background: Tubulointerstitial nephritis with IgM-positive plasma cells (IgMPC-TIN) is a newer disease about which there are many unclear points. Glucocorticoid therapy is effective in many cases of IgMPC-TIN; however, relapse during glucocorticoid tapering has been reported. Relapse and its treatment are poorly defined. Case Presentation: Case 1 was a 61-year-old man with renal dysfunction and proteinuria. Tubulointerstitial nephritis and IgM-positive plasma cells were observed in a renal biopsy. He was diagnosed with IgMPC-TIN accompanied by Fanconi syndrome and distal renal tubular acidosis (d-RTA). Prednisolone (PSL; 30 mg daily, 0.45 mg/kg/day) treatment was highly effective, and PSL was gradually tapered and discontinued after 1 year. However, 1 month after PSL discontinuation, therapeutic markers were elevated. Therefore, PSL (10 mg daily, 0.15 mg/kg/day) was administered, and the markers indicated improvement. Case 2 was a 43-year-old woman referred for renal dysfunction and proteinuria. Laboratory data revealed that she had primary biliary cholangitis (PBC), d-RTA, and Fanconi syndrome. A renal biopsy showed accumulation of IgM-positive plasma cells in the tubulointerstitium without any glomerular changes. A diagnosis of IgMPC-TIN was made and the patient was started on PSL (35 mg daily, 0.6 mg/kg/day). Therapeutic markers decreased immediately and PSL was discontinued after 1 year. Three months later, the proteinuria and Fanconi syndrome worsened. PSL treatment was restarted (20 mg daily, 0.35 mg/kg/day) and markers indicated improvement. Case 3 was a 45-year-old woman with renal dysfunction and proteinuria. Tubulointerstitial nephritis and IgM-positive plasma cells were observed in a renal biopsy. The patient had PBC, Sjögren syndrome, d-RTA, and Fanconi syndrome, and the diagnosis of IgMPC-TIN was made. The patient was started on PSL (30 mg daily, 0.4 mg/kg/day) and disease markers decreased immediately. However, when PSL was tapered to 15 mg daily (0.2 mg/kg/day), the patient’s serum IgM levels increased; therefore, we maintained the PSL at 15 mg daily (0.2 mg/kg/day). Conclusion: We report three cases of relapsed IgMPC-TIN associated with reduction or discontinuation of glucocorticoid therapy. In these cases, elevation of serum IgM preceded that of other markers such as urinary β2-microglobulin, proteinuria, and glycosuria. We recommend monitoring serum IgM levels while tapering glucocorticoids; a maintenance dose of glucocorticoid should be considered if relapse is suspected or anticipated.

12 August 2023 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HNHiroyuki Nishiyama
Hiroyuki Nishiyama
TITakamitsu Inoue
Takamitsu Inoue
YKYuichi Koizumi
Yuichi Koizumi
YKYusuke Kobayashi
Yusuke Kobayashi
HKHiroshi Kitamura
Hiroshi Kitamura
MYMotoko Yanagita
Motoko Yanagita

29 June 2023 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
SMSatoru Muto
Satoru Muto
TMTakeshi Matsubara
Takeshi Matsubara
TITakamitsu Inoue
Takamitsu Inoue
HKHiroshi Kitamura
Hiroshi Kitamura
KYKazuhiro Yamamoto
Kazuhiro Yamamoto
MYMotoko Yanagita
Motoko Yanagita